Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously untreated RAS wild-type, left-sided, unresectable metastatic colorectal cancer.